Related Experiment Videos
Defective Fas ligand production in lymphocytes from MS patients
B Macchi1, C Matteucci, U Nocentini
1Departments of Neuroscience, University of Rome Tor Vergata, Via di Tor Vergata 135 00133 Rome, Italy.
Neuroreport
|December 14, 2001
Summary
Multiple sclerosis patients show reduced Fas ligand (Fas-L) expression and release from lymphocytes. This impairment in Fas-L may affect the elimination of harmful autoreactive immune cells in multiple sclerosis.
Area of Science:
- Immunology
- Neuroscience
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- The Fas/Fas-ligand (Fas-L) pathway plays a critical role in immune cell apoptosis and regulation.
Purpose of the Study:
- To investigate Fas ligand (Fas-L) levels in cells from multiple sclerosis (MS) patients.
- To evaluate the expression and release of Fas-L in lymphocytes from MS patients with different disease courses compared to healthy donors.
Main Methods:
- A cross-sectional study design was employed.
- Peripheral blood mononuclear cells (PBMCs) from MS patients (relapsing-remitting and secondary-progressive) and healthy donors were stimulated with PHA.
- Fas and Fas-L levels (membrane-bound and soluble) were measured.
Main Results:
- Statistically significant decreased expression of Fas (p = 0.001) and release of Fas-L (p = 0.045) were observed in lymphocytes from MS patients compared to healthy controls.
- Fas-L production levels were inversely and highly significantly correlated with Expanded Disability Status Scale (EDSS) scores in MS patients.
Conclusions:
- Impaired Fas-L release in stimulated PBMCs from MS patients suggests a potential deficit in eliminating autoreactive T-cell clones in vivo.
- These findings may indicate a novel mechanism contributing to the pathogenesis of multiple sclerosis.